Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Total Non-Current Liabilities (2022 - 2026)

TriSalus Life Sciences has reported Total Non-Current Liabilities over the past 5 years, most recently at $49.1 million for Q1 2026.

  • For Q1 2026, Total Non-Current Liabilities fell 10.36% year-over-year to $49.1 million; the TTM value through Mar 2026 reached $49.1 million, down 10.36%, while the annual FY2025 figure was $59.0 million, 39.05% up from the prior year.
  • Total Non-Current Liabilities for Q1 2026 was $49.1 million at TriSalus Life Sciences, down from $59.0 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $59.0 million in Q4 2025 and troughed at $19.6 million in Q3 2023.
  • A 5-year average of $44.1 million and a median of $45.1 million in 2024 define the central range for Total Non-Current Liabilities.
  • Biggest five-year swings in Total Non-Current Liabilities: surged 104.11% in 2024 and later fell 10.36% in 2026.
  • Year by year, Total Non-Current Liabilities stood at $33.9 million in 2022, then dropped by 2.71% to $33.0 million in 2023, then grew by 28.56% to $42.5 million in 2024, then soared by 39.05% to $59.0 million in 2025, then dropped by 16.85% to $49.1 million in 2026.
  • Business Quant data shows Total Non-Current Liabilities for TLSI at $49.1 million in Q1 2026, $59.0 million in Q4 2025, and $58.2 million in Q3 2025.